Skip to main content
. 2013 Jul 9;2013:450963. doi: 10.1155/2013/450963

Table 1.

Schematic representation of the regions targeted by anti-HCV/E2 mAbs. Involved domains (DI, DII and DIII as well as the stem region) of HCV/E2 have been evidenced. In particular, DI has been described to be a discontinuous region containing the CD81 binding site; DII is predicted to possess the fusion peptide and DIII has been recently described to contain antigenic neutralization epitopes and to be involved in heterodimerization with E1.

graphic file with name CDI2013-450963.tab.001.jpg